These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 30695852)
1. Pharmaceuticals and Medical Devices: FDA Oversight. White RS; Issue Brief Health Policy Track Serv; 2018 Dec; 2018():1-44. PubMed ID: 30695852 [No Abstract] [Full Text] [Related]
2. Pharmaceuticals and Medical Devices: FDA Oversight. White RS; Issue Brief Health Policy Track Serv; 2016 Dec; 2016():1-74. PubMed ID: 28252887 [No Abstract] [Full Text] [Related]
3. Pharmaceuticals and medical devices: FDA oversight. Berry MD Issue Brief Health Policy Track Serv; 2013 Dec; ():1-123. PubMed ID: 24482893 [No Abstract] [Full Text] [Related]
4. Pharmaceuticals and medical devices: FDA oversight. Issue brief. Berry MD Issue Brief Health Policy Track Serv; 2012 Dec; ():1-79. PubMed ID: 23297449 [No Abstract] [Full Text] [Related]
5. Pharmaceuticals and medical devices: FDA oversight. End-of-year issue brief. Chaps NA Issue Brief Health Policy Track Serv; 2010 Jan; ():1-31. PubMed ID: 20217914 [No Abstract] [Full Text] [Related]
6. Pharmaceuticals and medical devices: FDA oversight. ; Berry MD; White RS Issue Brief Health Policy Track Serv; 2014 Dec; ():1-96. PubMed ID: 25775703 [No Abstract] [Full Text] [Related]
7. Pharmaceuticals and medical devices: FDA oversight. Issue brief. Thomson Reuters/West Issue Brief Health Policy Track Serv; 2011 Jan; ():1-39. PubMed ID: 21374841 [No Abstract] [Full Text] [Related]
8. Pharmaceuticals and medical devices: FDA oversight. ; Berry MD Issue Brief Health Policy Track Serv; 2012 Jan; ():1-86. PubMed ID: 22403845 [No Abstract] [Full Text] [Related]
9. Pharmaceuticals and Medical Devices: FDA Oversight. White RS; Issue Brief Health Policy Track Serv; 2017 Dec; 2017():1-43. PubMed ID: 29361661 [No Abstract] [Full Text] [Related]
10. Federal Right-to-Try Legislation - Threatening the FDA's Public Health Mission. Joffe S; Lynch HF N Engl J Med; 2018 Feb; 378(8):695-697. PubMed ID: 29320302 [No Abstract] [Full Text] [Related]
11. Muddied messages about FDA. Miller HI Nat Biotechnol; 2003 Jul; 21(7):732-3. PubMed ID: 12833084 [No Abstract] [Full Text] [Related]
12. Expanded Access to Investigational Drugs: What Physicians and the Public Need to Know about FDA and Corporate Processes. Finkelstein PE AMA J Ethics; 2015 Dec; 17(12):1142-6. PubMed ID: 26698587 [No Abstract] [Full Text] [Related]
13. Balancing government regulation against access to drugs: address to Seton Hall University School of Law, February 16, 2007. Meron D Seton Hall Law Rev; 2007; 37(4):929-39. PubMed ID: 18363219 [No Abstract] [Full Text] [Related]
14. The strange allure of state "right-to-try" laws. Zettler PJ; Greely HT JAMA Intern Med; 2014 Dec; 174(12):1885-6. PubMed ID: 25264589 [No Abstract] [Full Text] [Related]
15. Pharmaceuticals and medical devices: business practices. Issue brief. Steiner DJ Issue Brief Health Policy Track Serv; 2012 Dec; ():1-36. PubMed ID: 23297448 [No Abstract] [Full Text] [Related]
16. What ails the FDA? Okie S N Engl J Med; 2005 Mar; 352(11):1063-6. PubMed ID: 15784660 [No Abstract] [Full Text] [Related]
17. A Citizen's Pathway Gone Astray - Delaying Competition from Generic Drugs. Feldman R; Wang C N Engl J Med; 2017 Apr; 376(16):1499-1501. PubMed ID: 28248550 [No Abstract] [Full Text] [Related]
18. Off-label marketing and the First Amendment. Boumil MM N Engl J Med; 2013 Jan; 368(2):103-5. PubMed ID: 23234470 [No Abstract] [Full Text] [Related]
19. The FDA and the IOM report. Galson SK N Engl J Med; 2007 Dec; 357(24):2520-1; author reply 2521-2. PubMed ID: 18077820 [No Abstract] [Full Text] [Related]